Evidence map›Paper›PMID 36991306›Full record

ArticleJournal of neuro-oncology2023

Natural history of spinal cord metastasis from brain glioblastomas.

Aymeric Amelot, Louis-Marie Terrier, Gabrielle Cognacq, Vincent Jecko, Benoit Marlier, Romuald Seizeur, Evelyne Emery, Luc Bauchet, Vincent Roualdes, Jimmy Voirin and 16 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 2 countries.

Aymeric AmelotDepartment of Neurosurgery, CHRU de Tours, Tours, France. aymmed@hotmail.fr.
Louis-Marie TerrierDepartment of Neurosurgery, Clairval Private Hospital, Ramsay Generale de Sante, Marseille, France.
Gabrielle CognacqUniversity of Oxford, John Radcliffe HospitalHeadley Way, Headington, Oxford, OX3 9DU, Oxfordshire, United Kingdom.
Vincent JeckoDepartment of Neurosurgery A, CHU Pellegrin, Bordeaux, France.
Benoit MarlierDepartment of Neurosurgery, CHU de Reims, Reims, France.
Romuald SeizeurDepartment of Neurosurgery, CHU de La Cavale Blanche, Brest, France.
Evelyne EmeryDepartment of Neurosurgery, CHU de Caen, Caen, France.
Luc BauchetDepartment of Neurosurgery, Hôpital Saint Eloi - Gui de Chauliac, Montpellier, France.
Vincent RoualdesDepartment of Neurosurgery, CHU Laennec, Nantes, France.
Jimmy VoirinDepartment of Neurosurgery, Pasteur Hospital, HCC, Colmar, France.
Christophe JoubertDepartment of Neurosurgery, HIA St Anne, Toulon, France.
Emmanuel MandonnetDepartment of Neurosurgery, Lariboisière, AP-HP, Paris, France.
Leslie LemnosDepartment of Neurosurgery, CHU Dupuytren, Limoges, France.
Bertrand MathonDepartment of Neurosurgery, CHU Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France.
Pierre-Jean Le ResteDepartment of Neurosurgery, CHU Pontchaillou, Rennes, France.
Andres CocaDepartment of Neurosurgery, CHU Strasbourg, Strasbourg, France.
Antoine PetitDepartment of Neurosurgery, CHU Jean-Minjoz, Besançon, France.
Valérie RigauDepartment of Neuropathology, CHU Gui de Chauliac, Montpellier, France.
Karima MokhtariDepartment of Neuropathology, Pitié-Salpêtrière, AP-HP, Paris, France.
Audrey RousseauDepartment of Pathology, CHU d'Angers, Angers, France.
Philippe MetellusDepartment of Neurosurgery, Clairval Private Hospital, Ramsay Generale de Sante, Marseille, France.
Dominique Figarella-BrangerDepartment of Neuropathology, La Timone, AP-HM, Marseille, France.
Guillaume GauchotteDepartment of Pathology, CHU Nancy, Nancy, France.
Kaissar FarahDepartment of Neurosurgery, CHU La Timone, Marseille, France.
Johan PalludDepartment of Neurosurgery, GHU-Paris Psychiatrie Et Neurosciences, Hôpital Sainte-Anne, Paris, France.
Ilyess ZemmouraDepartment of Neurosurgery, CHRU de Tours, Tours, France.
Assistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Tours · FRGénérale de Santé · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Sainte-Anne · FRCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Reims · FRHôpital Civil, Strasbourg · FRHôpital de la Timone · FRHôpital d'Instruction des Armées Sainte-Anne · FRHôpital Dupuytren · FRHôpital Gui de Chauliac · FRHôpital Laennec · FRHôpital Maison Blanche · FRHôpital Pasteur · FRHôpital Pellegrin · FRHôpital Pontchaillou · FRHôpital Saint Eloi · FRUniversité de Caen Normandie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesSpinal cord metastasis arising from an intracranial glioblastoma is a rare and late event during the natural course of the disease. These pathological entities remain poorly characterized. This study aimed to identify and investigate the timeline, clinical and imaging findings, and prognostic factors of spinal cord metastasis from a glioblastoma.

methodsConsecutive histopathological cases of spinal cord metastasis from glioblastomas in adults entered in the French nationwide database between January 2004 and 2016 were screened.

resultsOverall, 14 adult patients with a brain glioblastoma (median age 55.2 years) and harboring a spinal cord metastasis were included. The median overall survival as 16.0 months (range, 9.8-22.2). The median spinal cord Metastasis Free Survival (time interval between the glioblastoma diagnosis and the spinal cord metastasis diagnosis) was 13.6 months (range, 0.0-27.9). The occurrence of a spinal cord metastasis diagnosis greatly impacted neurological status: 57.2% of patients were not ambulatory, which contributed to dramatically decreased Karnofsky Performance Status (KPS) scores (12/14, 85.7% with a KPS score ≤ 70). The median overall survival following spinal cord metastasis was 3.3 months (range, 1.3-5.3). Patients with a cerebral ventricle effraction during the initial brain surgery had a shorter spinal cord Metastasis Free Survival (6.6 vs 18.3 months, p = 0.023). Out of the 14 patients, eleven (78.6%) had a brain IDH-wildtype glioblastoma.

conclusionsSpinal cord metastasis from a brain IDH-wildtype glioblastoma has a poor prognosis. Spinal MRI can be proposed during the follow-up of glioblastoma patients especially those who have benefited from cerebral surgical resection with opening of the cerebral ventricles.

Indexed as

Brain NeoplasmsGlioblastomaSpinal Cord NeoplasmsAdultBrainHumansMiddle AgedPrognosisRetrospective StudiesGlioblastomaIDH-wildtypeSpinal cord metastasisSurvival

Identifiers

PMID36991306
OpenAlexW4361292550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.